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Abstract 
Background: Acute heart failure (AHF) after acute coronary syndrome (ACS) is the biggest 
complication with a poor prognosis in a long term. The infl uence of MMP-9 as proteolytic enzyme 
that degrades extracellular matrix in remodeling left ventricle was recognized. However, according 
to researcher’s knowledge, evaluation of the MMP-9 as a predictor of AHF after ACS was never 
reported. Objective: To fi nd out the serum level of MMP-9 in ACS with AHF higher than that 
without it, as well as to fi nd out the level of MMP-9 with risk of AHF after ACS. Method: The study 
used a cross-sectional study. Samples were collected by using a consecutive sampling technique 
among patients with ACS treated in ICCU of Public Hospital Dr Sardjito Yogyakarta, since June 
2008 to August 2010. Questionnaires were used to collect sample raw data. The level of MMP-9 
was examined a time at admission in ICCU before trombolysis was done. The heart failure had 
Killip II- IV scores. Factors infl uencing the incidence was analyzed by using multivariate analysis 
technique. A signifi cance level was at p< 0.05. The relative risk of acute heart failure at a certain level 
of MMP-9 (from cut-off value) was obtained after it was adjusted. Result: Among 122 subjects, 75 
was without AHF and 47 with AHF. Median of the level of MMP-9 in the whole sample of ACS was 
1248.55 ng/mL with a minimum of 170.50 ng/mL and maximum of 3058.40 ng/mL. Moreover, the 
level of MMP-9 in ACS with AHF (1700.81±740.43 ng/mL) was signifi cantly higher than ACS without 
AHF (1189.55±654.60 ng/mL) with p value = 0.000. Independent risk factor after the multivariate 
analysis was done indicates the level of MMP-9 above 1444 ng/mL (RR= 4.2) and the location 
of anterior infarction (RR= 2.9). Conclusion: In patients with ACS treated in ICCU of RSUP Dr 
Sardjito, the level of MMP-9 with AHF was higher than that without it. If the level of MMP-9 above 
1444 ng/mL, the possibility of AHF was 4.2 times.  
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Introduction 
Kyne et al. (2000) stated that heart failure 
is the biggest complication of ACS and a clinical 
problem with a poor prognosis in the long run 
about 50% to 70% among elderly patients1. 
Acute heart failure is associated with post-AMI 
mortality rates as expressed in ESC (2005) in a 
large randomized control trial study on patients 
hospitalized with decompensated heart failure, 
60-days mortality of 9.6%, combined death and 
60-days rehospitalization of 35%. The largest of 
death in acute heart failure was due to IMA of 30% 
in 12 months2. 
Remodeling as a concept that underlies 
the occurrence of heart failure has widely been 
studied, one of which was associated with the 
involvement of matrix metalloproteinase (MMP), 
especially after the ACS. There are 25 types of 
MMP and MMP-9 with gelatinase activity, which 
has wide infl uence on ventricular remodeling and 
heart failure (Armstrong, 2006 and Phatharajaree 
et al., 2007)3,4. According to Jong et al. (2006) the 
levels and activities of MMP-9 increased in patients 
with post-AMI acute heart failure, while those of 
MMP-2 did not show any difference5. 
The purposes of this study are to find 
out difference in serum levels of MMP 9 at ACS 
between with and without acute heart failure, and 
to examine the effect of increase in serum levels 
of MMP-9 at ACS on acute heart failure. 
METHOD 
The cross sectional study was conducted at 
the Intensive Cardiac Care Unit (ICCU) of Public 
Hospital Dr. Sardjito Yogyakarta from June 2008 
to August 2010. The subjects of the study were 
recruited consecutively until the required number 
of samples was reached. Anamnesis, physical 
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examination, 12 lead EKG examination, Killip 
score assessment, thoracic X-ray examination, 
serial CKMB and troponin I examination, standard 
laboratory tests including CBC, liver function 
(SGOT, SGPT, albumin), renal function (ureum, 
creatinine, uric acid), electrolytes, blood glucose, 
coagulation function (PPT and aPTT), lipid profi le 
examination, and examination of MMP-9 were 
done to each patient with a diagnosis of ACS at 
admission and meeting the inclusion criteria of 
study. The examinations were performed using 
the standard ELISA method in Central Prodia 
Laboratory of Jakarta, because the laboratory 
department of Public Hospital Dr. Sardjito could 
not been able to do. 
The diagnosis of ACS (in this study, they 
were STEMI and NSTEMI) was done with minimum 
of two of three myocardial infarction criteria, i.e. 
the presence of typical chest pain, EKG pattern 
changes, and increased markers of heart muscle 
damage (cardiac enzymes) (Jaffe, 2007)6. Acute 
heart failure is determined by Killip criteria, namely 
the class II, III or IV, which was fi rstly done at 
admission to ICCU and evaluated until the seventh 
day of treatment, to fi nd out whether or not there 
was change in Killip class of the class I (no acute 
heart failure) into class II , III or IV. 
Inclusion criteria for this study: (a) patients 
with diagnoses of STEMI, either with thrombolysis 
or without thrombolysis, and of NSTEMI with 
the onset of attacks in both groups of = 7 days 
associated with the incidence of acute heart 
failure as a complication of ACS, (b) male and 
female patients with age >18 and <75 years, and 
(c) patients are willing to participate in the study 
with informed consent. Meanwhile, the exclusion 
criteria in this study were: (a) patients with Primary 
PCI;  (b) patients with chronic heart failure before, 
(c) patients are pregnant. 
Outcomes assessed were difference in 
serum levels of MMP-9 between ACS with 
complication of acute heart failure and that without 
acute heart failure and the relative risk of acute 
heart failure at certain levels of MMP-9. The ethical 
feasibility of study was obtained from the Ethical 
Committee of Medicine and Health Research in 
Faculty of Medicine, Gadjah Mada University. 
The basic characteristics of subjects were 
presented in the average or median. Average 
difference in levels of MMP-9 was found in the two 
groups of ACS with heart failure and to be are not 
tested by Student's T Test or Mann-Whitney U Test. 
The signifi cance was accepted at p value <0.05, 
while the cut-off value of MMP-9 was determined 
by the ROC curve. The relative risk (RR) of MMP-
9’s infl uence on post-ACS acute heart failure was 
obtained after multivariate analysis was done using 
other risk factors (age, location of infarction). 
Results 
From June 2008 to August 2010, 135 
patients of ACS were obtained. There were 122 
subjects that met the criteria of study. The average 
age was 56.75 ± 9.82 years with the youngest age 
of 32 and the oldest one of 75. Average age with 
acute heart failure was 59.2±9.2 years, while that 
without it was 55.2 ± 9.9 years with a signifi cance 
value of p=0.027. Most of the subjects were 104 
male patients (85.2%), while the remaining was 
18 female ones (15.8%). No difference was found 
in the variables of thrombolysis, ACE inhibitors, 
diagnosis and the content of c Troponin I, while 
a signifi cant difference was found in location of 
infraction (p = 0.003). In this study, the overall level 
of MMP-9 on the condition of ACS was 1248.55 ng/
mL, a minimum of 170.50 ng/mL and a maximum of 
3058.40 ng/mL. Levels of MMP-9 were obtained at 
ACS with acute heart failure (1700.81 ± 740.43 ng/
mL) and that without acute heart failure (1189.55 
± 654.60 ng/mL) with a value of p = 0.000, as 
shown in Table 1. 
To fi nd out the effect of the increased levels 
of MMP-9 on the incidence of heart failure, the 
cut-off levels of MMP-9 was determined previously. 
From these ROC curves, it can be known that the 
cut-off value of the levels of MMP-9 was 1444 ng/
mL. In the cut-off value, the sensitivity of 67% and 
the specifi city of 62% were found. Based on the 
cut-off value of the levels of MMP-9, the subjects 
of this study were classifi ed into two groups, i.e. 
group with the levels of MMP-9 above the cut off 
value, amounting to 58 subjects (47.5%) and the 
group with high levels of MMP 9 under the cut-off 
value, amounting to 64 subjects (52.5%). The 
proportion of area under curve of the ROC curve 
was equal to 69.5%, meaning that there was a 
weak relationship between MMP-9 and post-ACS 
acute heart failure as shown in Figure 1. 
Table 2 indicates that the subjects with the 
levels of MMP-9 > 1444 with acute heart failure 
was 66%, while those with the levels of MMP-9 < 
1444 with heart failure was 31% with a signifi cance 
level of p = 0.000. It can be concluded that there 
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Table 2. The level of MMP-9 with the incidence of acute heart failure after ACS.
Variable ng/mL Heart failure n(%) No heart failure n(%) n(%) P 
MMP-9> 1444 31(66.0) 25(33.3) 56(47.5) 0.000 
MMP-9< 1444 16(34.0) 50(66.7) 66(52.5) 
Total 47(38.5) 75(61.5) 122(100) 
1 – Spesivity
1.0?0.80.60.40.20.0?
Sensitivity?
1.0?
0.8?
0.6?
0.4?
0.2?
0.0?
Figure 1. The ROC curve to determine the cut-off value of the levels 
of MMP-9 
Table 3.  Multivariate analysis on the variables of age, location of infarction, and the serum 
level of MMP-9 with acute heart failure after ACS 
Variable P RR/Exp(B) 
95% C.I. 
Lower Upper 
Age 0.053 2.277 0.991 5.232 
Location of infarction 0.010 2.963 1.298 6.765 
The level of MMP-9 0.001 4.217 1.843 9.646 
Tabel 1. The characteristics of the subjects of study  
Variable 
n (%)
P 
No acute heart Acute heart failure
failure 
Average age (year) 55.2±9.9 59.2±9.2 0.027 
< 60 year 49(65.3) 23(48.9) 0.073 
> 60 year 26(34.7) 24(51.1) 
Male 63(84) 41(87) 0.624 
Female 12(16) 6(13) 
ACE inhibitor, Yes 46(61.3) 31(66.0) 0.357 
No 29(38.7) 16(34.0) 
Trombolysis,  Yes 20(26.7) 15(31.9) 0.533 
No 55(73.3) 32(68.1) 
Troponin I < 7.17 ng/mL 40(53.3) 22(46.8) 0.483 
> 7.17 35(46.7) 25(53.2) 
Diagnosis STEMI      38(50.7) 27(57.4) 0,465 
NSTEMI 37(49.3) 20(42.6) 
Location of infarction 43(57.3) 14(24.8) 0.003 
Non anterior 
Anterior 32(42.7) 33(70.2) 
MMP-9 ng/mL 1189.55±654.60 1700.81 ±740.43 0.000 
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was a relationship between MMP-9 and the post-
ACS acute heart failure. 
By making a multivariate analysis with other 
risk factors lain, it can be found out that MMP-9 has 
the RR of 4,2 and the location of anterior infarction 
with the RR of 2.9, as shown in Table 3. 
Discussion 
In this study, there was difference in mean 
age between the groups with acute heart failure 
and those with a signifi cance value of p = 0.027, 
while those with acute heart failure was older 
than those without it. According to Tayebjee et 
al. (2005) the activities of TIMP and MMP has 
positive correlation, while TIMP-1 has a negative 
correlation if associated with age. The study use 
healthy subjects, so that the higher the age, the 
higher the risk of atherosclerosis or ACS, because 
the balance of MMP TIMP changed7. 
Sundström et al. (2004) shows that there 
was a very clear difference between MMP-9 and 
left ventricular remodeling, and the relationship 
was only signifi cant for patients male patients8. 
The result was different from our result of the 
study, because no difference was found in sex 
between the groups with acute heart failure and 
those without acute heart failure. 
Result of the study shows that the groups using 
the ACE inhibitor have larger proporsion, but acute 
heart failure did not show difference between those 
with ACE inhibitor and those without it (p = 0.357). 
It was different from results of the study conducted 
by Franzosi et al. (1998), indicating that the early 
use of ACE inhibitors (the acute phase was 0-36 
hours of the onset of myocardial infarction, followed 
by 4 6 weeks) signifi cantly reduced the incidence of 
nonfatal heart failure in 30 days, i.e. 6.1 cases per 
1000 pasien9. This was because the size of sample 
was much greater in the study (6687 in groups with 
ACE inhibitor and 6937 in control group). 
In the study, no more thrombolysis was 
done, and there was no signifi cant difference in the 
incidence of post-ACS acute heart failure between 
groups with thrombolysis and those without it 
(p = 0.533). This was different from Werf et al. 
(2003), stating that of 150,000 patients that were 
randomized to receive fi brinolytic therapy and the 
control of onset under 12 hours, fi brinolytic therapy 
still given better benefi t than control10. 
Results of the study were consistent with 
those of previous studies, i.e. there were the 
increased levels of MMP-9 on the condition of 
ACS, amounting to 1248.55 ng/mL with a minimum 
of 170.50 ng/mL and a maximum of 3058.40 ng/
mL In addition, the levels of MMP-9 on the ACS 
with heart failure (1700.81 ± 740.43 ng / mL) were 
signifi cantly higher than those on the ACS without 
acute heart failure (1189.55 ± 654.60 ng/mL) with 
p-value of 0.000. 
Savic et al. (2010) stated that other 
independent predictors of the increased risk of 
acute heart failure wee: anterior infarction and 
3-vessel disease CAD11. The proportion of age > 
60 years was higher with the complications of acute 
heart failure, but it was statistically insignifi cant (p = 
0.073). After multivariate analysis was done, it can 
be known that the role of MMP-9 as an independent 
predictor of acute heart failure indicates that the 
levels of MMP-9 above 1444 ng/mL in patients with 
ACS infl uenced on the incidence of acute heart 
failure by 4.2 times compared to the ACS with the 
levels of MMP-9 under 1444 ng / mL. According 
to our knowledge, there was no data about it 
before. Therefore, it becomes the contribution 
of knowledge on the infl uence of MMP-9 on the 
incidence of heart failure. 
Conclusion 
The serum levels of MMP-9 in patients 
of ACS with acute heart failure were higher 
than those without acute heart failure in ICCU 
department of RSUP Dr. Sardjito Yogyakarta. The 
ACS patients with the serum levels of MMP-9 > 
1444 ng/mL had a possibility of acute heart failure 
by 4.2 times compared to those of ACS with the 
MMP-9 of <1444 ng/mL. 
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